摘要:
The invention is a new architecture for a high frequency (HF) ballast with wireless communication interface. The new architecture integrates the RF wireless interface into the ballast. A user control transmits an RF control signal to a second antenna at the ballast site which provides the RF signal to the ballast which activates the fluorescent lamp. The ballast includes a transceiver/receiver, a communication decoder, a power control stage and a power stage. The transceiver/receiver receives the RF signal and communicates it to the communication decoder which acts as an interface to the power stage control. The power stage control controls the power stage that activates the fluorescent lamp. The communication decoder, power control stage, power stage and transceiver/receiver are located within the ballast enclosure which is an important part of the invention. If the power stage control is digital it may be combined with the communication decoder into one microprocessor or digital controller such as an ASIC. The communication decoder may be a serial interface. The transceiver/receiver is an RF integrated circuit. The ballast further includes an isolator to isolate the transceiver/receiver from the first antenna. The isolator may be capacitive.
摘要:
The present invention presents methods for gene expression monitoring that utilize microelectronic arrays to drive the transport and hybridization of nucleic acids. Procedures are described for generating mRNA expression samples for use in these methods from populations of cells, tissues, or other biological source materials, that may differ in their physiological and/or pathological state. Provided in the invention are methods for generating a reusable nucleic acid transcript library from mRNA in a sample of biological material. In order to improve gene expression monitoring on the microelectronic arrays, the transcripts are amplified to produce sample nucleic acid amplicons of a defined length. Because multiple sample amplicons may be selectively hybridized to controlled sites in the electronic array, the gene expression profiles of the polynucleotide populations from different sources can be directly compared in an array format using electronic hybridization methodologies. Also provided in the invention are methods for detecting the level of sample amplicons using electronically assisted primer extension detection, and utilizing individual test site hybridization controls. The hybridization data collected utilizing the improved methods of the present invention will allow the correlation of changes in mRNA level with the corresponding expression of the encoded protein in the biological source material, and thus aid in studying the role of gene expression in disease.
摘要:
An actuator assembly in a disc drive includes a track accessing arm, a load beam and a slider. A proximal end of the load beam is mounted to the track accessing arm and a distal end of the load beam carries the slider proximate to a rotatable data storage disc. The load beam transmits a load force to the slider in the direction of the data storage disc. A support beam extends from the track accessing arm and supports a load force reducer between the support arm and the load beam. The load force reducer is operatively coupled between the support beam and the load beam for reducing the load force during take-off and landing of the slider relative to the disc surface.
摘要:
A digital decoder, used in a reconfigurable circuit, for decoding digital pulses includes a phase indicator module having inputs coupled to a reference pulse input and a data pulse input. The phase indicator module has timing information outputs that provide logic values indicative of rising and falling edges of pulses occurring on the reference pulse input and the data pulse input. A phase decoder module has inputs coupled to the timing information outputs, and outputs decoded binary data values. In operation, the phase decoder module compares at least two of the logic values at the timing information outputs with a signal representative leading and trailing edges of a pulse applied to one of the phase inputs to determine a pulse arrival order sequence on the phase inputs and thereby provide the decoded binary data values.
摘要:
In certain embodiments of the invention, a serializer has a transfer stage that transfers N-bit parallel data from a relatively slow timing domain to a relatively fast timing domain and a serializing stage that converts the parallel data into serialized data. Between the transfer stage and the serializing stage is an update stage that buffers the data and can be used to toggle the serializer between an N−1 operating mode and an N+1 operating mode.
摘要:
The present invention relates to a method for identifying compounds that modulate the activity of p300/CBP. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified lysine-CoA inhibitor binding site, L1 loop, electronegative pocket, or electronegative groove of the HAT domain of p300/CBP and testing the compound for its ability to modulate the activity of p300/CBP. Compositions and methods for preventing or treating diseases or disorders associated with p300/CBP are also provided as is a method for producing a semi-synthetic HAT domain.
摘要:
A bandgap circuit is provided, which includes a current source, a voltage boost circuit, a voltage input circuit, a voltage equalizer circuit, and a voltage output circuit. The current source provides a first current, a second current, and a third current, which are equal to one another. The voltage boost circuit provides a boost voltage by a single current path. The voltage input circuit receives the first and the second currents, and provides a first input voltage and a second input voltage based on the boost voltage. The voltage equalizer circuit receives the first and the second input voltages and equalize the two input voltages. The voltage output circuit provides a bandgap reference voltage according to the third current.
摘要:
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
摘要翻译:本发明涉及新型合成取代的杂环化合物和含有能够抑制或拮抗受体酪氨酸激酶家族(Tropomysosin Related Kinases,Trk),特别是神经生长因子(NGF)受体TrkA的家族的合成取代的杂环化合物和药物组合物。 本发明还涉及这些化合物在治疗和/或预防疼痛,癌症,再狭窄,动脉粥样硬化,牛皮癣,血栓形成或与异常髓鞘或脱髓鞘有关的疾病,病症或损伤或与异常活动有关的疾病或病症 的NGF受体TrkA。
摘要:
A method is disclosed for conducting a query to transform data in a pre-existing database, the method comprising: collecting database information from the pre-existing database, the database information including inconsistent dimensional tables and fact tables; running an entity discovery process on the inconsistent dimensional tables and the fact tables to produce entity mapping tables; using the entity mapping tables to resolve the inconsistent dimensional tables into resolved dimensional tables; and running the query on a resolved database to obtain a query result, the resolved database including the resolved dimensional table.
摘要:
This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.